# Sermorelin References: The GHRH(1-29) Literature, Cited

> Sermorelin references: the full citation list behind this digest — PubMed and DOI links for every GHRH(1-29) study on the pediatric, adult, body-composition, and pharmacokinetic record.

Every quantitative claim on this site maps to a numbered source below, with a PubMed or DOI link. The full GHRH(1-29) reference list.

## Primary sources

The references below are the [GHRH(1-29) references](/references) behind every figure on this site — the pediatric growth trials, the adult GH/IGF-1 work, the pharmacokinetic study, the drug-class body-composition and cognition trials, the editorials that set the limits, and the recent reviews. Each entry carries a DOI or PubMed link. Numbering matches the inline citation markers used across the research, dosage, half-life, comparison, and FAQ pages.

## References

[1] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[2] Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/
[3] Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. https://pubmed.ncbi.nlm.nih.gov/8329825/
[4] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[5] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[6] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. ClinicalTrials.gov NCT00257712. https://pubmed.ncbi.nlm.nih.gov/22869065/
[7] Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009;296(5):E1085-92. https://pubmed.ncbi.nlm.nih.gov/19240251/
[8] Hernández M, et al. Subcutaneous treatment with growth hormone-releasing hormone for short stature. Horm Res. 1988;30:252-7. https://pubmed.ncbi.nlm.nih.gov/2907992/
[9] Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. https://pubmed.ncbi.nlm.nih.gov/18057338/
[10] Koutkia P, Canavan B, Breu J, et al. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA. 2004;292(2):210-218. https://pubmed.ncbi.nlm.nih.gov/15249570/
[11] Sigalos JT, Pastuszak AW. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. https://pubmed.ncbi.nlm.nih.gov/32257855/
[12] Bagno L, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(13):10846-10859. https://pubmed.ncbi.nlm.nih.gov/25797248/
[13] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. https://pubmed.ncbi.nlm.nih.gov/39537825/
[14] Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. Int J Mol Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/42123471/
[15] Bagno LL, et al. Efficacy of a growth hormone-releasing hormone agonist in a murine model of cardiometabolic heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2023. https://pubmed.ncbi.nlm.nih.gov/36897749/

---

The GHRH(1-29) record stencilled onto raw concrete — the pulsatile-GH mechanism, the studied doses, the body-composition data filed where it belongs as tesamorelin, the formerly-approved-then-withdrawn history set straight, and the thin adult-safety line sprayed in caution-orange; no clinic behind the wall and nothing here dosed, compounded, or sold.